Ono Pharmaceutical Company, Ltd.
83 articles with Ono Pharmaceutical Company, Ltd.
Numab Therapeutics and Ono Pharmaceutical Enter Development and License Agreement for Multispecific Antibody Candidate Involving Novel Immuno-Oncology Target
Numab Therapeutics AG and Ono Pharmaceutical Co., Ltd. announced that Ono has exercised its option to enter into a development and license agreement for a multispecific antibody candidate that was generated through a research collaboration between the two companies initiated in 2017.
Endevica Bio isn’t trying to cure cancer. Instead, it is focused on improving cancer patients’ quality of life and preventing deaths.
Neurimmune expands drug discovery collaboration with Ono Pharmaceutical in the field of neurodegenerative diseases
Neurimmune AG announced that it has signed an expanded drug discovery collaboration agreement with Ono Pharmaceutical Co., Ltd.
ONO PHARMA USA Announces Initiation of Phase 1 Study of ONO-4685, an Anti-PD-1/CD3 Bispecific Antibody, in Patients with Relapsed or Refractory T-cell Lymphoma in the U.S
ONO PHARMA USA , INC announced the initiation of a Phase 1 study of ONO-4685, an anti-PD-1/CD3 bispecific antibody, in patients with relapsed or refractory T-cell Lymphoma in the U.S.
Caris Life Sciences and Ono Pharmaceutical Announce Strategic Collaboration Leveraging Caris' Novel, Blood-Based cNAS Molecular Profiling Assay Across Several Ono Clinical Studies
Caris Life Sciences® and Ono Pharmaceutical Co., Ltd. announced a strategic collaboration to leverage Caris' best-in-class molecular profiling, including its novel, liquid biopsy circulating nucleic acids sequencing assay, across several studies beginning later this year.
10/1/2021Biopharma companies and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
ONO PHARMA USA, INC. announced the appointment of David Trexler as Chief Commercial Officer of OPUS.
Ribon Therapeutics Announces License Agreement with Ono Pharmaceutical Co., Ltd. to Develop and Commercialize RBN-2397 In Japan, South Korea, Taiwan and ASEAN Countries
Ribon Therapeutics, a clinical stage oncology company developing therapeutics targeting stress support pathways, today announced it has entered into an exclusive license agreement with Ono Pharmaceutical Co., Ltd., for the development and commercialization of RBN-239
AGC Biologics Enters into Partnership as a CDMO with Ono Pharmaceuticals to Manufacture Biopharmaceuticals at Clinical Development Stage
AGC Biologics, a global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced it is partnering with Ono Pharmaceutical Co., Ltd. (ONO) to manufacture new, innovative biopharmaceuticals at the clinical development stage. ONO is a R&D-oriented pharmaceutical company committed to discovering and developin
Opdivo (nivolumab) Demonstrates Statistically Significant Overall Survival Benefit Versus Chemotherapy in Patients with Advanced Esophageal Cancer
Opdivo demonstrated a 23% reduction in the risk of death and 2.5-month improvement in median overall survival compared to chemotherapy
Bayer, Bristol-Myers Squibb and Ono Pharmaceutical enter into a clinical collaboration agreement to investigate Stivarga® (regorafenib) and Opdivo® (nivolumab) as combination therapy in patients with metastatic colorectal cancer
Combination of regorafenib and nivolumab vs. regorafenib alone to be evaluated in patients with micro-satellite stable metastatic colorectal cancer
Bayer, Bristol-Myers Squibb and Ono Pharmaceutical Co. have teamed up to study the most common type of metastatic colorectal cancer (mCRC).
Schrödinger announced receipt of a milestone payment from Ono Pharmaceutical Co., Ltd. as part of a collaboration leveraging Schrödinger’s advanced computational platform to develop novel therapeutic candidates acting on the therapeutic target selected by Ono.
Forty Seven, Inc. and Ono Pharmaceutical Co., Ltd. Sign Regional License Agreement to Develop, Manufacture and Commercialize 5F9 in Japan, South Korea, Taiwan and Select Countries in Southeast Asia
Forty Seven, Inc., a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, and Ono Pharmaceutical Co., Ltd. today announced an exclusive license agreement for the development, manufacture and commercialization of 5F9, Forty Seven’s monoclonal antibody against CD47.
6/27/2019Biotech and pharma companies from across the globe share pipeline and business updates.
The decision, which is likely to be appealed, will allow Dana-Farber to license the technology.
Biotech and pharma companies from across Europe and Asia provide updates on pipeline and business activities.
Ono Pharmaceutical Co., Ltd. announced that the companies have signed a drug discovery research collaboration to jointly discover and develop novel, efficacious treatments to address unmet medical needs in a specific neurological disease.
Repare Therapeutics Announces a Strategic Partnership Agreement With ONO Pharmaceutical Co., Ltd. for Repare’s Polθ Inhibitor Program in Japan and Selected Territories in Asia
Repare Therapeutics, Inc. announced that it has entered into an exclusive strategic research, development and commercialization partnership with ONO Pharmaceutical Co., Ltd., for Repare’s small molecule Polθ inhibitor program in Japan, South Korea, Taiwan, Hong Kong, Macau and ASEAN countries, excluding mainland China.
This second collaboration involves the discovery of candidate MAbs against an undisclosed target and leverages the power of Integral Molecular's MPS Antibody Discovery platform.